Mosaic chromosome 20q deletions are more frequent in the aging population.
暂无分享,去创建一个
Nathaniel Rothman | Stephen J Chanock | Meredith Yeager | Michael Dean | Mitchell J Machiela | N. Rothman | S. Chanock | M. Yeager | S. Gapstur | V. Stevens | M. Dean | M. Machiela | N. Caporaso | L. Goldin | Neil Caporaso | Susan M Gapstur | Weiyin Zhou | Lynn Goldin | Victoria L Stevens | Weiyin Zhou
[1] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[2] T. S. Wan. Cancer Cytogenetics , 2017, Methods in Molecular Biology.
[3] William Wheeler,et al. Characterization of large structural genetic mosaicism in human autosomes. , 2015, American journal of human genetics.
[4] M. McCarthy,et al. Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.
[5] S. Gabriel,et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.
[6] Stephen J Chanock,et al. Detectable clonal mosaicism in the human genome. , 2013, Seminars in hematology.
[7] Kirsten R. McEwen,et al. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions , 2013, Clinical Epigenetics.
[8] C. Stiller,et al. Incidence, survival and prevalence of myeloid malignancies in Europe. , 2012, European journal of cancer.
[9] William Wheeler,et al. Detectable clonal mosaicism and its relationship to aging and cancer , 2012, Nature Genetics.
[10] Ingo Ruczinski,et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer , 2012, Nature Genetics.
[11] M. Hirai,et al. Microarray CGH analyses of chromosomal 20q deletions in patients with hematopoietic malignancies. , 2012, Cancer genetics.
[12] A. Stamatoullas,et al. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. , 2011, Leukemia research.
[13] A. Jankowska,et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.
[14] Juan R. González,et al. R-Gada: a fast and flexible pipeline for copy number analysis in association studies , 2010, BMC Bioinformatics.
[15] P. D. Dal Cin,et al. Identification of del(20q) in a subset of patients diagnosed with idiopathic thrombocytopenic purpura , 2009, British journal of haematology.
[16] Valeria Nofrini,et al. Totipotent stem cells bearing del(20q) maintain multipotential differentiation in Shwachman Diamond syndrome , 2009, British journal of haematology.
[17] Kai Wang,et al. Copy Number Variation Detection via High-Density SNP Genotyping. , 2008, CSH protocols.
[18] Ronald A. DePinho,et al. How stem cells age and why this makes us grow old , 2007, Nature Reviews Molecular Cell Biology.
[19] K. Ohyashiki,et al. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. , 2006, Cancer genetics and cytogenetics.
[20] P. Deloukas,et al. Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignancies , 2004, British journal of haematology.
[21] S. E. Jacobsen,et al. MDS/AML‐associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: Evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q) , 2004, Genes, chromosomes & cancer.
[22] A. Green,et al. Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] D. Steensma,et al. Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia? , 2003, Leukemia research.
[24] D. Gudbjartsson,et al. A high-resolution recombination map of the human genome , 2002, Nature Genetics.
[25] Hartmut Geiger,et al. The aging of lympho-hematopoietic stem cells , 2002, Nature Immunology.
[26] Pardis C Sabeti,et al. Linkage disequilibrium in the human genome , 2001, Nature.
[27] T. L. Hood,et al. Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes , 2000, Oncogene.
[28] P. Wang,et al. Refinement of the smallest commonly deleted segment of chromosome 20 in malignant myeloid diseases and development of a PAC-based physical and transcription map. , 2000, Genomics.
[29] C. Mecucci,et al. Cytogenetics of myelodysplastic syndromes. , 1999, Forum.
[30] A. Green,et al. Molecular genetics and cytogenetics of myeloproliferative disorders. , 1998, Bailliere's clinical haematology.
[31] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[32] G. Dewald,et al. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients. , 1996, American journal of clinical pathology.
[33] P. Morel,et al. Cytogenetics of myelodysplastic syndromes. , 1996, Seminars in hematology.
[34] G. Dewald,et al. Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3,996 patients with malignant hematologic neoplasms. , 1993, Cancer genetics and cytogenetics.
[35] F. Mitelman,et al. Cytogenetic analysis in the diagnosis of acute leukemia , 1992, Cancer.